trial · primary record
Pembrolizumab
Colon Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2029-09-30 |
| Primary endpoint | Major Pathologic Response (MPR) rate by Blinded Independent Pathologic Review (BIPR) |
| Registry ID | NCT07808151 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:12.198Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07808151
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.